Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis.

Latimer N, Lord J, Grant RL, O'Mahony R, Dickson J, Conaghan PG; National Institute for Health and Clinical Excellence Osteoarthritis Guideline Development Group..

BMJ. 2009 Jul 14;339:b2538. doi: 10.1136/bmj.b2538.

2.

Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis.

Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, Bertagnolli MM, Arber N, Levin B, Meinert CL, Martin B, Pater JL, Goss PE, Lance P, Obara S, Chew EY, Kim J, Arndt G, Hawk E; Cross Trial Safety Assessment Group..

Circulation. 2008 Apr 22;117(16):2104-13. doi: 10.1161/CIRCULATIONAHA.108.764530. Epub 2008 Mar 31.

3.
5.

An economic model of long-term use of celecoxib in patients with osteoarthritis.

Loyd M, Rublee D, Jacobs P.

BMC Gastroenterol. 2007 Jul 4;7:25.

6.

Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib.

Farkouh ME, Greenberg JD, Jeger RV, Ramanathan K, Verheugt FW, Chesebro JH, Kirshner H, Hochman JS, Lay CL, Ruland S, Mellein B, Matchaba PT, Fuster V, Abramson SB.

Ann Rheum Dis. 2007 Jun;66(6):764-70. Epub 2007 Apr 5.

7.

Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance.

Borer JS, Simon LS.

Arthritis Res Ther. 2005;7 Suppl 4:S14-22. Epub 2005 Sep 15. Review.

Supplemental Content

Loading ...
Support Center